EinhornLHRapoportBNavriRM, et al.
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple day-chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer2017;
25: 303–308.
3.
HeskethPJKrisMGBaschE, et al.
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol2017;
35: 3240–3261.
4.
EllebaekEHerrstedtJ.Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy. Curr Opin Support Palliat Care2008;
2: 28–34.
5.
BadarTCortesJBorthakurG, et al.
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int2015;
2015: 497597.
6.
MattiuzziGNCortesJEBlambleDA, et al.
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer2010;
116: 5659–5666.
UchidaMIkesueHKatoK, et al.
Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am J Health Syst Pharm2013;
70: 343–349.
9.
BrakenJBRaemaekersJMKoopmansPP, et al.
Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukemia. Eur J Cancer1993;
29A: 515–518.
10.
BrownGWPaesDBrysonJ, et al.
The effectiveness of a single intravenous dose of ondansetron. Oncology1992;
49: 273–278.
